



(43) International Publication Date
30 June 2016 (30.06.2016)

(10) International Publication Number
WO 2016/101024 A1

(51) International Patent Classification:

A61K 31/444 (2006.01) *A61P 9/04* (2006.01)
A61K 9/22 (2006.01)

(21) International Application Number:

PCT/AU2015/050820

(22) International Filing Date:

21 December 2015 (21.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2014905194 22 December 2014 (22.12.2014) AU

(71) Applicant: **BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITED** [AU/AU]; 75 Commercial Road, Melbourne, Victoria 3004 (AU).

(72) Inventor: **KAYE, David**; 16 Hornby Street, Beaumaris, Victoria 3193 (AU).

(74) Agent: **DAVIES COLLISON CAVE**; Level 10, 301 Coronation Drive, Milton, Queensland 4064 (AU).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD OF TREATMENT

(57) Abstract: The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.



WO 2016/101024 A1